C‐reactive protein lowering with rosuvastatin in the METEOR study

. Peters SAE, Palmer MK, Grobbee DE, Crouse JR III, O’Leary DH, Raichlen JS, Bots ML (Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands; Keele University, Keele, UK; Wake Forest University School of Medicine, Winston‐Salem, NC, USA; Caritas Carney Hospital, Boston, MA, USA; AstraZeneca, Wilmington, DE, USA). C‐reactive protein lowering with rosuvastatin in the METEOR study. J Intern Med 2010; 268: 155–161. Objectives. In addition to its LDL‐C‐lowering effects, statin treatment reduces the level of C‐reactive protein (CRP). Long‐term data on this effect in low‐risk populations are limited. Furthermore, whether the CRP reduction is a consequence of LDL‐C lowering or occurs independently remains unclear. We studied these aspects in the Measuring Effects on intima media Thickness: an Evaluation Of Rosuvastatin (METEOR) study, a randomized placebo‐controlled trial amongst 984 low‐risk subjects. Methods. METEOR is a randomized placebo‐controlled trial that evaluated the effect of 40 mg of rosuvastatin on 2‐year change in carotid intima media thickness (CIMT) amongst 984 low‐risk patients (10‐year Framingham risk